Status: Not yet recruiting
Phase I Clinical Study to Evaluate the Safety and Efficacy of 3SC009 Monotherapy for Patients With Advanced Solid Tumors
This study includes two parts, different part has different administration frequencies of 3SC009.
Participants needed: 100
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Shenyang Sunshine Pharmaceutical Co., LTD.Updated: Sep 11, 2026
Eligibility criteria
Males and/or females over age 18 [+4]
Known uncontrolled or symptomatic central nervous system metastatic disease. [+4]